Hyperventilation Versus Exercise Testing Sensitivity in Exercise Induced Asthma
NCT ID: NCT03063424
Last Updated: 2019-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2011-06-30
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)
NCT00807534
Diagnosis of EIB in Young Elite Athletes (13-18 y)
NCT03587675
Exercise Challenge in a Cold Chamber
NCT02026492
Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)
NCT06336681
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD
NCT03679312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
Eucapnic voluntary hyperventilation
Exercise challenge on a cycle ergometer
Asthmatics with EIB
Eucapnic voluntary hyperventilation
Exercise challenge on a cycle ergometer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eucapnic voluntary hyperventilation
Exercise challenge on a cycle ergometer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject should have an average expiratory volume per second (FEV1) ≥ 80% of the predicted value (post bronchodilatation) at the time of the initial visit.
* The subject must have had a positive methacholine test at the first visit of the study demonstrating the presence of bronchial hyperreactivity.
* The subject must have asthma control as defined by 2010 Canadian Thoracic Society consensus, with the obvious exception of limitations related to physical activity.
* The subject must have at the questionnaire significant symptoms of exercise-induced bronchospasm for more than 6 months.
* The subject should not have a positive history of eczema, urticaria or allergic rhinitis for life.
* The subject should have a FEV1 ≥ 80% of the predicted value and an FEV1 / FVC (Forced vital capacity) ratio of ≥70% at the time of the initial visit.
* The subject should have a negative methacholine test at the first visit of the study.
* The subject should not exhibit symptoms considered clinically compatible with EIB diagnosis.
Exclusion Criteria
* The subject should not suffer from clinically significant concomitant diseases that may compromise the course of the study.
* The subject should not have taken per os or intravenously steroids in the 8 weeks prior to the study.
* The subject should not have experienced significant symptoms of respiratory tract infection (viral or bacterial) in the 8 weeks prior to the study.
* The subject must not have participated in another study during the month preceding the date of enrollment of this study.
* The subject should not have smoked within the last 6 months.
* The subject doesn't show up for all 3 visits or doesn't complete all required exams.
* The subject develops a respiratory tract infection, an acute exacerbation of his asthma or any other conditions that compromise his participation in the required examinations.
* The subject has a pre-test FEV1 of less than 80%.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian Grondin-Beaudoin
Clinical Professor, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Larivée
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Université de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.